RxDoctor Payments Data

Eric Medina, MD

Ophthalmology · Boca Raton, FLNPI 1407269301

Payments from drug & device makers

$8,305in general payments, 2019–2025

Across 140 payments — averaging $59.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$4K
  • AbbVie$1K
  • Sight Sciences, Inc.$454
  • Bausch & Lomb Americas Inc.$347
  • Aerie Pharmaceuticals, Inc.$245
  • Glaukos Corporation$209
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$2,85834%
  • Food & beverage$5,44766%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,305 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$714,283
Medicare patients
858
Services billed
13,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine107$154,448
LumiganBimatoprost62$29,055
Cyclosporine38$26,138
RhopressaNetarsudil Mesylate42$24,995
XiidraLifitegrast19$23,455
MieboPerfluorohexyloctane/Pf17$13,891
Prednisolone Acetate399$13,859
Ketorolac Tromethamine314$12,150
VyzultaLatanoprostene Bunod14$8,070
Tobramycin-DexamethasoneTobramycin/Dexamethasone149$6,953
Brimonidine Tartrate135$6,862
Latanoprost535$5,888
Tobradex StTobramycin/Dexamethasone21$4,896
CombiganBrimonidine Tartrate/Timolol15$4,746
Travoprost21$4,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$1,239$188,248184 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$347$45,41550 claims
Aerie Pharmaceuticals, Inc.Rhopressa$245$24,99542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →